SCHEDULE: Capital International Investors Holds 6.4% of Zimmer Biomet

Capital International Investors has reported a beneficial ownership of 6.4% in Zimmer Biomet Holdings, Inc., holding 12,438,366 shares.

Summary

• Capital International Investors (CII) has filed a Schedule 13G, indicating beneficial ownership of 12,438,366 shares of Zimmer Biomet Holdings, Inc. common stock.
• This represents 6.4% of the total outstanding shares, which are estimated to be 193,462,482.
• CII has sole voting power over 12,279,364 shares and sole dispositive power over 12,438,366 shares.
• The filing is made under Rule 13d-1(b), classifying CII as an investment adviser.
• The filing date is June 30, 2026, with the certification signed on July 29, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine Schedule 13G filing indicating a significant but not controlling stake, without new strategic information.

Positives

• Capital International Investors maintains a significant stake (6.4%) in Zimmer Biomet, suggesting confidence in the company's long-term prospects.
• The filing confirms a substantial number of shares are held with sole dispositive power, indicating clear control over these holdings.

Negatives

• The filing does not provide any new strategic information or performance updates, making it a routine disclosure.

Risks

• As a holder of 6.4% of the shares, Capital International Investors' future investment decisions could influence market perception and stock price.
• The filing does not detail any specific risks associated with Zimmer Biomet's operations, focusing solely on ownership.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like Capital International Investors, indicating significant but typically non-controlling stakes in public companies. This filing places Zimmer Biomet within the context of active institutional investment in the medical device sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can influence market sentiment and trading activity.
• Management: The filing is a routine disclosure and does not directly impact management operations, but signals continued institutional interest.

Next Steps

• Capital International Investors will continue to hold its shares in Zimmer Biomet, subject to its investment strategy.
• Future changes in ownership percentage above 5% would trigger new filings.

Key Dates

Keywords

Zimmer Biomet, Capital International Investors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Shareholder